XTLB Profile
XTL Biopharmaceuticals Ltd. is a biopharmaceutical company focused on the acquisition and development of innovative pharmaceutical products aimed at treating autoimmune diseases. The company's primary asset is hCDR1, a drug candidate poised for Phase II clinical trials. This candidate is targeted for the treatment of systemic lupus erythematosus and Sjogren's syndrome, two debilitating autoimmune conditions. XTL Biopharmaceuticals has entered into a licensing agreement with Yeda Research and Development Company Limited, which grants it rights for the research, development, and commercialization of hCDR1 across various indications.
The company’s research and development efforts are directed towards addressing unmet medical needs in autoimmune diseases, a sector with significant therapeutic potential. hCDR1 represents a promising approach to modulating the immune system's response, potentially offering new treatment options for patients with complex autoimmune disorders.
XTL Biopharmaceuticals was previously known as Xenograft Technologies Ltd. and rebranded in July 1995 to reflect its renewed focus on biopharmaceuticals. Since its incorporation in 1993, the company has been dedicated to advancing treatments for autoimmune diseases, leveraging its expertise and strategic partnerships to drive innovation.
Headquartered in Ramat Gan, Israel, XTL Biopharmaceuticals continues to build its portfolio through strategic alliances and development programs. Its ongoing commitment to addressing challenging medical conditions underscores its role in the evolving landscape of biopharmaceuticals.
|
